Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Eli Lilly is spending $6.3 billion to buy London-based Centessa Pharmaceuticals, betting on a portfolio of neuroscience medicines that could be part of the…
Eli Lilly agreed to buy Centessa Pharmaceuticals, the maker of an experimental drug meant to combat sleeping conditions, for roughly $6.3 billion in cash.…
Centessa definitive merger proxy (DEFM14A) for the Lilly acquisition. Per the company's May 22, 2026 8-K, the Hart-Scott-Rodino antitrust waiting period…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Eli Lilly agreed to acquire Centessa Pharmaceuticals for $38/share (~$6.3B equity) plus up to $1.5B in CVR payments ($7.8B total), gaining OX2R agonist cleminorexton with Phase 2a best-in-class data across narcolepsy T1/T2 and idiopathic hypersomnia. Sell-side frames the orexin class as a $15-20B market opportunity. Structured as a UK scheme of arrangement; the deal has de-risked since announcement: the HSR antitrust waiting period expired May 21, 2026 and the English High Court cleared a scheme shareholder meeting for June 12, 2026, with court sanction still to follow. Still pending; expected close Q3 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Centessa Pharmaceuticals plc (this deal) | 2026 | $7.8B | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2026 deals · Eli Lilly and Company deals · Neurology deals